- New fellowship integrates regenerative medicine, emerging biotechnology, longevity medicine, and artificial intelligence
- Program targets physicians and point-of-care regenerative medicine providers
- Curriculum reflects ISSCA’s continued investment in advanced physician credentialing
FOR IMMEDIATE RELEASE
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a comprehensive new fellowship designed for physicians and point-of-care regenerative medicine providers.
The curriculum integrates regenerative medicine modalities, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence — reflecting what ISSCA describes as the increasingly multidisciplinary nature of modern regenerative medicine practice.
ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries. The new fellowship is positioned as the organization’s most comprehensive credential to date, intended to prepare physicians for the convergence of clinical practice, biotechnology, and computational tools.
“The physicians who will lead this field aren’t going to specialize in just one modality — they’ll need to be fluent across regenerative medicine, biotechnology, and increasingly, AI-driven clinical tools,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This fellowship is ISSCA’s answer to that shift.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
